Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a cash flow conversion efficiency ratio of 0.625x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.73 Million) by net assets ($-45.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AMRX equity to assets ratio to measure how much of total assets are equity-financed.
Amneal Pharmaceuticals, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AMRX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Amneal Pharmaceuticals, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amneal Pharmaceuticals, Inc. Class A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Angel Yeast Co Ltd
SHG:600298
|
0.146x |
|
Sabra Healthcare REIT Inc
NASDAQ:SBRA
|
0.035x |
|
Shanghai Lujiazui Finance & Trade Zone Development Co Ltd A
SHG:600663
|
0.058x |
|
Exchange Income Corporation
TO:EIF
|
0.112x |
|
360 ONE WAM LIMITED
NSE:360ONE
|
-0.160x |
|
Charoen Pokphand Foods Public Company Limited
BK:CPF
|
0.042x |
|
Montage Gold Corp.
TO:MAU
|
0.006x |
|
Porsche Automobil Holding SE
XETRA:PAH3
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2025)
The table below shows the annual cash flow conversion efficiency of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Amneal Pharmaceuticals, Inc. Class A Com.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.96 Million | $339.99 Million | 57.017x | +960.53% |
| 2024-12-31 | $-44.54 Million | $295.10 Million | -6.626x | -217.54% |
| 2023-12-31 | $61.30 Million | $345.58 Million | 5.637x | +1709.14% |
| 2022-12-31 | $208.93 Million | $65.10 Million | 0.312x | -52.71% |
| 2021-12-31 | $366.97 Million | $241.82 Million | 0.659x | -37.98% |
| 2020-12-31 | $356.74 Million | $379.00 Million | 1.062x | +21508.92% |
| 2019-12-31 | $346.79 Million | $1.71 Million | 0.005x | -98.24% |
| 2018-12-31 | $896.36 Million | $250.23 Million | 0.279x | +144.77% |
| 2017-12-31 | $-375.58 Million | $234.19 Million | -0.624x | +4.65% |
| 2016-12-31 | $-175.94 Million | $115.06 Million | -0.654x | -16.52% |
| 2015-12-31 | $-186.87 Million | $104.88 Million | -0.561x | -- |
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms … Read more